NASDAQ:ARTV Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis $12.02 +0.11 (+0.92%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$11.71▼$12.0550-Day Range N/A52-Week Range$9.71▼$16.00Volume65,745 shsAverage Volume110,337 shsMarket Capitalization$279.83 millionP/E RatioN/ADividend YieldN/APrice Target$21.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesInsider TradesSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesInsider TradesSEC FilingsTrends Get Artiva Biotherapeutics alerts: Email Address Artiva Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside76.8% Upside$21.25 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.05Based on 2 Articles This WeekInsider TradingAcquiring Shares$30 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.60) to ($2.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.72 out of 5 starsMedical Sector345th out of 909 stocks 4.5 Analyst's Opinion Consensus RatingArtiva Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArtiva Biotherapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Artiva Biotherapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ARTV. Previous Next 0.0 Dividend Strength Dividend YieldArtiva Biotherapeutics does not currently pay a dividend.Dividend GrowthArtiva Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARTV. Previous Next 1.6 News and Social Media Coverage News SentimentArtiva Biotherapeutics has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Artiva Biotherapeutics this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added Artiva Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Artiva Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $29,999,976.00 in company stock and sold $0.00 in company stock.Read more about Artiva Biotherapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Artiva Biotherapeutics are expected to grow in the coming year, from ($3.60) to ($2.49) per share.Read more about Artiva Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Artiva Biotherapeutics Stock (NASDAQ:ARTV)Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Read More ARTV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARTV Stock News HeadlinesSeptember 4 at 10:27 AM | markets.businessinsider.comBuy Rating Affirmed for Artiva Biotherapeutics on Promising AlloNK Developments and Trial OptimismSeptember 1, 2024 | americanbankingnews.comArtiva Biotherapeutics (NASDAQ:ARTV) Stock Rating Reaffirmed by Needham & Company LLCSeptember 7, 2024 | Crypto 101 Media (Ad)Perfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankAugust 31, 2024 | americanbankingnews.comArtiva Biotherapeutics (NASDAQ:ARTV) Receives Outperform Rating from WedbushAugust 30, 2024 | markets.businessinsider.comBuy Rating Affirmed for Artiva Biotherapeutics Amidst Clinical Advancements and Strong FinancialsAugust 30, 2024 | markets.businessinsider.comArtiva Biotherapeutics, Inc. (ARTV) Receives a Buy from WedbushAugust 30, 2024 | finanznachrichten.deArtiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 30, 2024 | markets.businessinsider.comArtiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsSeptember 7, 2024 | Crypto 101 Media (Ad)Perfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankAugust 29, 2024 | fool.comThis Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative TreatmentAugust 15, 2024 | uk.investing.comArtiva Biotherapeutics shares get Overweight ratingAugust 13, 2024 | finance.yahoo.comArtiva Biotherapeutics, Inc. (ARTV)August 13, 2024 | markets.businessinsider.comBuy Rating Affirmed: Artiva Biotherapeutics’ Promising AlloNK Cell Therapy in the Autoimmune SpaceAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Artiva Biotherapeutics Amid Promising NK Cell Therapy DevelopmentsAugust 13, 2024 | benzinga.comArtiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish PitchJuly 31, 2024 | morningstar.comArtiva Biotherapeutics Inc ARTVJuly 28, 2024 | 247wallst.comInsider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up SharesJuly 23, 2024 | investing.comArtiva Biotherapeutics Inc (ARTV)See More Headlines Receive ARTV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artiva Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/07/2024Next Earnings (Estimated)12/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:ARTV Previous SymbolNASDAQ:ARTV CUSIPN/A CIK1817241 Webwww.artivabio.com Phone(858) 267-4467FaxN/AEmployees81Year FoundedN/APrice Target and Rating Average Stock Price Target$21.25 High Stock Price Target$23.00 Low Stock Price Target$18.00 Potential Upside/Downside+76.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$33.74 million Price / Sales8.29 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares23,280,000Free FloatN/AMarket Cap$279.83 million OptionableN/A BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Fred Aslan M.D. (Age 49)President, CEO & Director Comp: $917.3kDr. Peter Flynn Ph.D. (Age 50)Co-Founder & Strategic Advisor Comp: $499.37kMs. Jennifer Kinsbruner Bush Esq. (Age 49)J.D., Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer Comp: $630.31kMr. Christopher P. Horan (Age 57)Chief Technical Operations Officer Comp: $612.23kMs. Neha Krishnamohan (Age 37)CFO & Executive VP of Corporate Development Dr. Thorsten Graef M.D. (Age 48)Ph.D., Chief Medical Officer Dr. Heather Raymon Ph.D. (Age 60)Senior Vice President of Research & Early Development Mr. Eugene HelselSenior Vice President of Regulatory AffairsDr. K. C Lim Pharm.D.Senior Vice President of Clinical OperationsMore ExecutivesKey CompetitorsSana BiotechnologyNASDAQ:SANATyra BiosciencesNASDAQ:TYRAARS PharmaceuticalsNASDAQ:SPRYBioLife SolutionsNASDAQ:BLFSProthenaNASDAQ:PRTAView All CompetitorsInsidersYong-Jun HuhBought 2,083,332 shares on 7/22/2024Total: $25.00 M ($12.00/share)Global Strategic Fund I VenbioBought 416,666 shares on 7/22/2024Total: $5.00 M ($12.00/share)View All Insider Transactions ARTV Stock Analysis - Frequently Asked Questions How have ARTV shares performed this year? Artiva Biotherapeutics' stock was trading at $11.77 at the start of the year. Since then, ARTV shares have increased by 2.1% and is now trading at $12.02. View the best growth stocks for 2024 here. When did Artiva Biotherapeutics IPO? Artiva Biotherapeutics (ARTV) raised $167 million in an IPO on Friday, July 19th 2024. The company issued 13,920,000 shares at a price of $12.00 per share. When did Artiva Biotherapeutics' quiet period expire? Artiva Biotherapeutics' quiet period expired on Wednesday, August 28th. Artiva Biotherapeutics had issued 13,920,000 shares in its initial public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. During Artiva Biotherapeutics' quiet period, underwriters and any insiders involved in the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of Artiva Biotherapeutics? Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARTV) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredHere’s A Painful Truth and 100% Fact About The Stocks You’re HoldingCharles Payne here, and I want to let you in on an uncomfortable truth that long term investors and retirees n...Unstoppable Prosperity | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredLast Call for Crypto Summit (RSVP FREE)The Dow recently shed nearly 1,000 points in a single day… Big tech stocks are getting slaughtered… And ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
